PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvictoâ„¢ (lutetium (177Lu)…
Safest SARMs For Muscle Growth 2025: CrazyBulk IntroducesEffectiveSARMs For Bulking, Cutting and Strength in USA.
Albany, New York, July 15, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…